Pilot Study to Identify Biomarkers That May Predict Response to High Dose IL-2
- Determine the relationship of peripheral blood lymphocyte phenotype pattern in patients
with metastatic renal cell carcinoma or metastatic melanoma to response to high-dose
- Determine the relationship of peripheral blood mononuclear cells gene microarray
patterns in patients with metastatic renal cell carcinoma or metastatic melanoma to
response to high-dose IL-2.
- Determine the frequency of mutations on genes encoding for IL-2 receptor A and B.
OUTLINE: Patients receive high-dose aldesleukin (IL-2) as part of standard treatment on days
1 and 8. Courses repeat every 3 weeks in the absence of disease progression or unacceptable
Patients undergo blood collection at baseline, prior to beginning course 2, and 4 weeks
after the completion of course 2. Samples are analyzed using peripheral blood cytometry,
gene microarray analysis, and IL-2 receptor single-nucleotide polymorphism techniques.
Primary Purpose: Treatment
Relationship of peripheral blood lymphocyte phenotype to response to high-dose aldesleukin (IL-2)
Ralph Hauke, MD
University of Nebraska
United States: Federal Government
|UNMC Eppley Cancer Center at the University of Nebraska Medical Center||Omaha, Nebraska 68198-7680|